Antibiotic Pipeline Shrinks 35 Percent in Five Years as WHO Races to Steer Development Toward Priority Superbugs

Overview

The global antibiotic pipeline is contracting at the very moment drug-resistant infections are accelerating. A benchmark report published on March 11 by the Access to Medicine Foundation found that large research-based pharmaceutical companies now have just 60 antibiotic development projects, down 35 percent from 92 in 2021. On the same day, the World Health Organization released three new target product profiles designed to guide investment toward the pathogens most likely to kill patients who contract resistant infections. Taken together, the two announcements illustrate a paradox at the heart of modern medicine: the scientific understanding of antimicrobial resistance has never been sharper, yet the economic incentives to act on it remain broken.

The Pipeline Numbers

The 2026 Antimicrobial Resistance Benchmark assessed 15 pharmaceutical companies, including seven large research-based firms and eight small and medium enterprises. Among the major companies, three firms account for the overwhelming majority of antibiotic research and development. GSK leads with 30 products in its pipeline, followed by Shionogi and Pfizer with eight each, according to Euronews. The remaining four large firms contribute comparatively little.

The report identified seven innovative late-stage projects with potential to address high-priority pathogens, including treatments for resistant gram-negative bacteria, multidrug-resistant tuberculosis, and invasive fungal infections. Two of those projects have already crossed the regulatory finish line: the FDA approved zoliflodacin and gepotidacin for uncomplicated gonorrhea, marking the first new oral treatment options for that infection in decades.

But the broader trajectory is unmistakable. The pipeline shrank by roughly a third in five years, and the benchmark’s authors warned that small and medium enterprises, which increasingly shoulder the burden of early-stage innovation, face financial fragility that could erase their contributions before any candidate reaches patients. “Without significant change, AMR will cause a devastating rise in deaths from preventable infections over the next two decades,” said Jayasree K. Iyer, CEO of the Access to Medicine Foundation.

WHO Defines What the World Needs

The WHO’s three new target product profiles, developed under the EU4Health programme in partnership with the European Commission, attempt to channel limited research resources toward the areas of greatest clinical need.

The first TPP focuses on severe multidrug-resistant gram-negative infections caused by carbapenem-resistant Enterobacterales, Acinetobacter baumannii, and Pseudomonas aeruginosa. These pathogens dominate intensive care units and are responsible for bloodstream infections, hospital-acquired pneumonia, and ventilator-associated bacterial pneumonia. The second targets vancomycin-resistant Enterococcus faecium, a leading cause of bloodstream infections in immunosuppressed and critically ill patients that carries elevated mortality rates. The third addresses bacterial meningitis across both community and healthcare settings, where resistance to penicillins and cephalosporins is rising. Approximately one in six people affected by bacterial meningitis dies, and one in five survivors experiences long-term disabilities including hearing loss, epilepsy, and cognitive impairment.

“We need a reliable pipeline with new antibacterial agents that are innovative, affordable, accessible to all those who need them,” said Dr. Yvan Hutin, Director of Antimicrobial Resistance at the WHO.

The profiles serve as blueprints rather than mandates. They specify the clinical scenarios, patient populations, and resistance profiles that new drugs should address, giving pharmaceutical companies and academic researchers a shared reference point. But blueprints do not pay for clinical trials.

The Economic Failure

The core problem is well documented: antibiotics are among the least profitable drugs a company can develop. Effective stewardship demands that new antibiotics be held in reserve and used sparingly, which suppresses sales volume. Short treatment courses further limit revenue. Meanwhile, development costs and regulatory hurdles remain comparable to those for drugs that treat chronic conditions and generate recurring income over decades.

This economic mismatch has driven most large pharmaceutical companies out of antibiotic research. The benchmark found that only two companies, Innoviva and Otsuka, have detailed plans to ensure their products reach patients in low- and middle-income countries, where drug-resistant infections exact the heaviest toll. The pediatric gap is even more alarming: only five of 35 assessed projects are designed specifically for children under five, and no child-friendly antibiotic formulations have been registered in 17 sub-Saharan African countries with high AMR burden.

A STAT News analysis published in early March argued that artificial intelligence, often cited as a potential accelerant for drug discovery, cannot solve the underlying market failure. AI can screen millions of molecular compounds in days rather than years and can identify candidates from unconventional sources, but without reforms to how antibiotics are purchased and reimbursed, promising molecules will continue to die in the funding gap between discovery and clinical trials. The authors, one an academic researcher and the other leading the AMR Action Fund, contended that structural changes to procurement, financing, and regulation are prerequisites for any technological tool to deliver on its potential.

The Scale of the Threat

The WHO’s 2025 Global Antibiotic Resistance Surveillance Report found that one in six laboratory-confirmed bacterial infections worldwide showed resistance to antibiotic treatment, with rates climbing an average of five to 15 percent annually across more than 40 monitored antibiotics between 2018 and 2023. Resistance is highest in the WHO South-East Asian and Eastern Mediterranean regions, where one in three reported infections is resistant. In the European Union alone, antibiotic-resistant infections contribute to more than 35,000 deaths annually.

Looking further ahead, modeling studies project 39 million deaths attributable to bacterial antimicrobial resistance between 2025 and 2050 if current trends continue. A Frontiers in Pharmacology review published on March 19 emphasized that addressing WHO-priority pathogens will require integrated approaches spanning molecular biology, pharmacology, clinical translation, and public health, including antimicrobial stewardship, surveillance, and One Health frameworks that account for resistance spread across human, animal, and environmental reservoirs.

What Comes Next

Several policy mechanisms are under discussion. Pull incentives, such as guaranteed purchase commitments or transferable exclusivity vouchers, aim to decouple antibiotic revenue from sales volume. The United Kingdom’s subscription model, which pays companies a fixed annual fee for access to new antibiotics regardless of how many doses the National Health Service uses, has been in pilot since 2022. The United States Congress has considered but not passed the PASTEUR Act, which would create a similar framework. The benchmark report urged governments to act with greater urgency, noting that industry efforts are being “outpaced by drug resistance.”

Meanwhile, the WHO is convening a global consultation meeting on March 26 and 27 to launch a multi-year antimicrobial resistance learning and workforce capacity building program. The initiative reflects a recognition that even if new drugs emerge, healthcare systems in many countries lack the trained personnel and laboratory infrastructure to use them effectively.

The simultaneous publication of a shrinking pipeline report and new drug development blueprints on March 11 encapsulated the current moment: the science points clearly to what is needed, and the market continues to walk away.